<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120663</url>
  </required_header>
  <id_info>
    <org_study_id>S59726</org_study_id>
    <nct_id>NCT03120663</nct_id>
  </id_info>
  <brief_title>Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)</brief_title>
  <acronym>TAPAS</acronym>
  <official_title>Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective observational study, the investigators want to document
      pharmacokinetic/pharmacodynamic (PK/PD) target attainment of frequently used antimicrobials
      in an adult non critically ill surgery population (abdominal surgery, traumatology and septic
      orthopedic surgery). Furthermore, the investigators want to identify risk factors for not
      attaining predefined PK/PD targets.

      The antibiotics of interest are amoxicillin(-clavulanic acid), flucloxacillin,
      piperacillin-tazobactam, meropenem and clindamycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this research proposal, the primary objective is to describe PK parameters (area under the
      curve (AUC), clearance (Cl), distribution volume (Vd) and half life (T1/2)) for the
      antibiotics of interest (amoxicillin(-(clavulanic acid), flucloxacillin,
      piperacillin-tazobactam, meropenem and clindamycin) for this adult non critically ill surgery
      population.

      Besides, the investigators want to document pharmacokinetic/pharmacodynamic (PK/PD) target
      attainment of frequently used ABs in this population and to identify risk factors, for
      example augmented renal clearance (ARC), for not attaining predefined PK/PD targets.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The % of time that free concentrations of antimicrobials are above minimal inhibitory concentrations (MIC) or antimicrobial European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints</measure>
    <time_frame>During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.</time_frame>
    <description>Per antimicrobial of interest, we will determine the % of time that free concentrations are above minimal inhibitory concentrations (MIC) or antimicrobial EUCAST breakpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.</time_frame>
    <description>Per antimicrobial of interest, we will determine the pharmacokinetic parameter the area under the plasma concentration versus time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl)</measure>
    <time_frame>During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.</time_frame>
    <description>Per antimicrobial of interest, we will determine the pharmacokinetic parameter clearance (Cl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.</time_frame>
    <description>Per antimicrobial of interest, we will determine the pharmacokinetic parameter the volume of distribution (Vd).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T1/2)</measure>
    <time_frame>During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.</time_frame>
    <description>Per antimicrobial of interest, we will determine the pharmacokinetic parameter the half life (T1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for target non attainment</measure>
    <time_frame>During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.</time_frame>
    <description>Multivariate analysis will be performed with target attainment as outcome. This will allow to identify risk factors for target non attainment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Surgery</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin-clavulanic acid</intervention_name>
    <description>During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.
Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² .</description>
    <other_name>meropenem</other_name>
    <other_name>flucloxacillin</other_name>
    <other_name>piperacillin-tazobactam</other_name>
    <other_name>clindamycin</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Per patient, blood samples during 1 antimicrobial dosing interval and the measured creatinine
      clearance based on an 8-hour urinary collection (CrCl8h) will be collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult non-critically ill surgery patient admitted at the abdominal, trauma or septic
        orthopaedic surgery wards from the University Hospitals Leuven
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Every adult non-critically ill surgery patient admitted at the abdominal, trauma or septic
        orthopaedic surgery wards from the University Hospitals Leuven treated with multiple doses
        of one of the antimicrobials of interest (i.e. intravenous (IV) amoxicillin(-clavulanic
        acid), flucloxacillin, piperacillin-tazobactam, meropenem, oral or IV clindamycin) is
        eligible for inclusion.

        Exclusion Criteria:

          -  age ≤ 18 years

          -  treatment restrictions corresponding to a Do Not Reanimate code

          -  pregnancy

          -  lactation

          -  renal replacement therapy

          -  planned discharge or surgery in the coming antimicrobial dosing interval making
             sampling impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Declercq, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Declercq, PharmD</last_name>
    <phone>003216342340</phone>
    <email>peter.declercq@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Spriet, PhD</last_name>
    <phone>003216341261</phone>
    <email>isabel.spriet@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Declercq, PharmD.</last_name>
      <phone>+321642340</phone>
      <email>peter.declercq@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter Declercq, PharmD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>peter declercq</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>antimicrobials</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>augmented renal clearance</keyword>
  <keyword>non critically ill</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

